NRX Pharmaceuticals Says Mid-Stage Trial Shows BriLife COVID-19 Vaccine May Have Potential Against Delta Coronavirus Variant
NRX Pharmaceuticals Says Mid-Stage Trial Shows BriLife COVID-19 Vaccine May Have Potential Against Delta Coronavirus Variant
NRX製藥公司表示，中期試驗顯示BriLife新冠肺炎疫苗可能具有對抗Delta冠狀病毒變異株的潛力
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊